← Tra cứu cổ phiếu

iShareInvest Research

HNX · Quý 2/2026

PPP

Dược phẩm Phong Phú

Analysis of business results & financial statements · Quý 2/2026

▲▲ Improving positively

Trailing net profit reached 29.7bn, rose 10.7bn compared with the same period last year. Key positives came from higher gross profit and better other profit. Offsetting pressure came mainly from higher tax, higher administrative expenses, and higher selling expenses. Detailed impact is shown below:

See what is changing ↓
P/E
6.53x
P/B
1.21x
EPS
3,033
BVPS
16,311
ROE
21.7%
ROA
17.3%
Market price
19,800
19 Oct 2026

What Is Changing

On a TTM 2026Q2 basis, PPP has not accelerated revenue sharply, but profitability is improving visibly — the growth momentum has held across consecutive periods. Profit growth is driven mainly by better operations rather than scale expansion — a foundation that tends to be more durable.

Profit bridge

Vs last year · TTM

  1. Gross profit
  2. Other profit
  3. Tax
  4. Administrative expenses
  5. Selling expenses
Unit: VND bn. Green bars support profit; red bars reduce profit.

A single data point, or a trajectory?

Latest eight quarters · Quý 2/2026

MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Revenue42.137.441.332.531.134.936.533.4
LNST9.110.86.43.34.34.55.44.7
Net margin21.68%28.88%15.55%10.09%13.90%12.97%14.88%14.09%

Revenue

42bn

Net income

9bn

Net margin

21.68%

A closer look at what is happening inside the business

A company's statements are read with the questions that fit its type of business.

01

Is the profit sustainable?

Margins are improving and earnings quality is solid — a durable foundation for ROE.

Revenue Growth

▲

Is growth real and durable?

Trailing-12-month revenue grew 12.9% year on year — not from a single spike: quarterly growth stepped up from −3% to +36%.

3 of the last 4 quarters grew year on year.

Revenue TTM
153bn
+12.9%
Latest quarter YoY
+36%
accelerating

What is driving the margin?

▲▲

Net margin expanded to 19.33%, rising 5.4pp. The main driver is Gross margin rose 2.1pp, moving in line with the stronger net margin (with additional support from Other profit / Revenue rose 4.0pp and Net financial result / Revenue rose 0.3pp).

Most of the margin increase comes from non-core items — core operations have not kept pace, this is a margin expansion to watch carefully.

Net Margin
19.33%
+5.4pp
Gross Margin
37.75%
+2.1pp
SG&A / Revenue
19.12%
−0.2pp

TTM YoY · 2025Q2 -> 2026Q2

Cash Flow

▲▲

Is profit converting into cash?

With leverage safe, cash flow shows the self-funding capacity. Operating cash flow reached 16.8bn against investing cash flow of -9.2bn (annual cash-flow figures for 2025).

Post-investment cash flow was positive +7.6bn. Financing cash flow was negative +6.9bn.

CFO / net income was 1,01 lần.

After spending +1.7bn on fixed-asset investment, the business generated trailing free cash flow of +28.1bn.

Earnings Quality

●

How much income is non-core?

Non-core income makes up 22.9% of pre-tax profit — worth monitoring.

Within that, net financial result at +5.7%, other profit at +17.2% of PBT.

Non-core / PBT
22.9%
moderate
Net financial / PBT
5.7%
Other profit / PBT
17.2%
02

Is capital being used efficiently?

Return on capital rose, but cash cycle lengthened by 2.8 days — working capital needs watching.

Is capital being deployed efficiently?

▲▲

ROIC expanded to 18.36%, rising 3.2pp. That translates to 18.36 in after-tax operating profit for every 100 units of operating capital. Both NOPAT margin rose 2.1pp and capital turnover rose 0.06x, with invested capital holding roughly steady — capital-return quality improved from both sides.

Capital efficiency improved through NOPAT margin — this is a quality-led improvement when operating profit leads.

Working Capital Efficiency

●

Cash conversion cycle lengthened by 2.8 days versus the same period last year. The main moves came from DIO rose 9.0 days, DSO fell 6.9 days, and DPO fell 0.7 days.

Working capital cycle lengthened mainly due to slower inventory turnover — more capital is being tied up in inventory.

Cash conversion cycle remains stretched

CCC stands at 141.2 days, suggesting that working capital remains tied up for a relatively long operating cycle.

Inventory turnover is slowing

DIO increased by +9.0 days, suggesting more capital is being tied up in inventories.

DuPont

What drives ROE?

Net margin 19.3% +5.4pp
Asset turnover 0.90x +0.03x
Financial leverage 1.25x +0.02x
ROE 21.7% +6.9pp

ROE rose from 14.8% to 21.7% — all three components improved, with net margin contributing the most.

03

Is financial risk significant?

Financial risk is low — the company has net cash and CFO reached 16.8bn.

Leverage & Liquidity

▲

Leverage looks fairly comfortable, with net debt / equity at −0.02x and interest coverage at 160.74x.

At present, short-term debt accounts for 100.0% of total debt, cash equals 333.9% of debt, and total debt stands at 1.3bn.

Net Debt / Equity
−0.02x
+0.00x
Interest Coverage
160.74x
−137.61x
Cash / Debt
333.9%
+99.9pp
Short-term Debt / Total Debt
100.0%
0.0pp

TTM YoY · 2025Q2 -> 2026Q2

Short-term refinancing pressure is meaningful

Short-term debt accounts for 100.0% of total debt, raising near-term refinancing needs.

Balance Sheet

▲

The asset structure shows capital being allocated increasingly efficiently. Balance sheet is exceptionally sound — liabilities at 0.27x equity, with a net cash position equivalent to 0.02x equity.

Inventory ended the period at 40.1bn, roughly 22.7% of total assets.

Over the last 12 months, working capital released 1.0bn of cash, mainly thanks to lower receivables and higher payables. Pressure from higher inventories only partly offset that benefit.

Research synthesis

What this reporting period is showing

The business is heading the right way, but the current picture is still at partial confirmation — not yet a fully clean case. The positive points have clearly improved, showing the operating base is better than before. The brighter spot is operating efficiency, with net margin improving 5.4 pp. The next item to monitor is the earnings mix, when non-core contribution is 17.2%. The main risk still sits in working capital is tied up too long in the operating cycle, with CCC extended to 141 days.

  • Improvement: operating efficiency is getting better, with trailing-12M net margin at 19.33% after expanding 5.4pp versus the same period last year.
  • Watchpoint: cash flow is currently keeping pace with accounting earnings, with CFO / net income at 1.01x. Even so, net financial result still accounts for 17.2% of PBT, so the earnings mix still needs monitoring.
  • Key risk: working capital remains tied up for too long, with cash cycle at 141.2 days.

Questions for the next period

  1. Whether revenue sustains its +12,9% YoY pace or begins to slow.

  2. Whether margins hold around the current 19.33% level or narrow again.

  3. Whether operating cash flow holds its 16.8bn (cumulative for 2025) level in upcoming periods or weakens.

From one stock to the whole portfolio

Where does this stock stand
among the rest of your investments?

Each stock is only one part of the wider picture. Looking at investments side by side makes their contribution, risks and opportunities across the portfolio clearer.

How much does this stock
contribute to the portfolio?

Its weight and influence across the assets held for investment.

Is the portfolio
well balanced?

How holdings, sectors and asset groups are distributed in relation to overall risk.

What other opportunities
or risks may be present?

What becomes visible only when investments are viewed together rather than one ticker at a time.

View my portfolio